Gynaecological malignancy in pregnancy

Pregnancy; Malignancy; Cervical; Ovarian; Consensus; Multidisciplinary

[1] Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. The Lancet. 2012; 379: 558–569.

[2] Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2013; 24: vi160–vi170.

[3] China S, Sinha Y, Sinha D, Hillaby K. Management of gynaecological cancer in pregnancy. The Obstetrician & Gynaecologist. 2017; 19: 139–146.

[4] de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. The Lancet Oncology. 2018; 19: 337–346.

[5] Di Ciaccio PR, Campbell B, Mason KD, Shanavas M, Greenwood M, Gregory GP, et al. Lymphoma during pregnancy: a multicentre study by the Australasian lymphoma alliance. Blood. 2021; 138: 882.

[6] Latimer J. Gynaecological malignancies in pregnancy. Current Opinion in Obstetrics & Gynecology. 2007; 19: 140–144.

[7] Amant F, Van Calsteren K, Halaska MJ, Beijnen J, Lagae L, Hanssens M, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. In Reed N, Green JA, Gershenson DM, Siddiqui N, Connor R (eds.) Rare and uncommon gynecological cancers (pp. 209-227). 1st edn. Springer: Berlin. 2011.

[8] Amant F, Van Calsteren K, Vergote I, Ottevanger N. Gynecologic oncology in pregnancy. Critical Reviews in Oncology/Hematology. 2008; 67: 187–195.

[9] Lee Y, Roberts C, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy‐associated cancer in Australia, 1994–2008: a population‐based linkage study. BJOG: An International Journal of Obstetrics & Gynaecology. 2012; 119: 1572–1582.

[10] Eibye S, Kjær SK, Mellemkjær L. Incidence of pregnancy-associated cancer in Denmark, 1977–2006. Obstetrics & Gynecology. 2013; 122: 608–617.

[11] Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary management of cancer during pregnancy. JCO Oncology Practice. 2020; 16: 545–557.

[12] Halaska MJ, Uzan C, Han SN, Fruscio R, Dahl Steffensen K, Van Calster B, et al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the international network on cancer, infertility and pregnancy. To be published in International Journal of Gynecologic Cancer. 2019. [Preprint].

[13] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[14] Michalet M, Dejean C, Schick U, Durdux C, Fourquet A, Kirova Y. Radiotherapy and pregnancy. Radiotherapy and Pregnancy. Cancer/Radiotherapie. 2022; 26: 417–423.

[15] Mosavi F, Ullenhag G, Ahlström H. Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma. Upsala Journal of Medical Sciences. 2013; 118: 91–97.

[16] Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Research and Treatment. 2016; 160: 347–360.

[17] Kyrgidis A, Lallas A, Moscarella E, Longo C, Alfano R, Argenziano G. Does pregnancy influence melanoma prognosis? A meta-analysis. Melanoma Research. 2017; 27: 289–299.

[18] Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, et al. Breast cancer diagnosed during pregnancy. JAMA Oncology. 2015; 1: 1145.

[19] Pearl JP, Price RR, Tonkin AE, Richardson WS, Stefanidis D. SAGES guidelines for the use of laparoscopy during pregnancy. Surgical Endoscopy. 2017; 31: 3767–3782.

[20] Rollins MD, Chan KJ, Price RR. Laparoscopy for appendicitis and cholelithiasis during pregnancy: a new standard of care. Surgical Endoscopy. 2004; 18: 237–241.

[21] Ball E, Waters N, Cooper N, Talati C, Mallick R, Rabas S, et al. Evidence-based guideline on laparoscopy in pregnancy: commissioned by the British Society for Gynaecological Endoscopy (BSGE) endorsed by the Royal College of Obstetricians & Gynaecologists (RCOG). Facts, Views & Vision in ObGyn. 2019; 11: 5.

[22] van Gerwen M, Maggen C, Cardonick E, Verwaaijen EJ, van den Heuvel-Eibrink M, Shmakov RG, et al. Association of chemotherapy timing in pregnancy with congenital malformation. Obstetrical & Gynecological Survey. 2021; 76: 732–733.

[23] Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, et al. Maternal and fetal outcomes after therapy for hodgkin or non-hodgkin lymphoma diagnosed during pregnancy. JAMA Oncology. 2016; 2: 1065.

[24] Maggen C, Wolters VERA, Cardonick E, Fumagalli M, Halaska MJ, Lok CAR, et al. Pregnancy and cancer: the INCIP project. Current Oncology Reports. 2020; 22: 17.

[25] Maggen C, Wolters VERA, Van Calsteren K, Cardonick E, Laenen A, Heimovaara JH, et al. Impact of chemotherapy during pregnancy on fetal growth. The Journal of Maternal-Fetal & Neonatal Medicine. 2022; 35: 10314–10323.

[26] Freret TS, Exman P, Mayer EL, Little SE, Economy KE. Birthweight and chemotherapy exposure in women diagnosed with breast cancer during pregnancy. American Journal of Perinatology. 2022; 39: 554–561.

[27] Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Annals of Oncology. 2019; 30: 1601–1612.

[28] Webb KE, Sakhel K, Chauhan SP, Abuhamad AZ. Adnexal mass during pregnancy: a review. American Journal of Perinatology. 2015; 32: 1010–1006.

[29] Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. New England Journal of Medicine. 2015; 373: 1824–1834.

[30] Lu D, Ludvigsson JF, Smedby KE, Fall K, Valdimarsdóttir U, Cnattingius S, et al. Maternal cancer during pregnancy and risks of stillbirth and infant mortality. Journal of Clinical Oncology. 2017; 35: 1522–1529.

[31] Schwab R, Anic K, Hasenburg A. Cancer and pregnancy: a comprehensive review. Cancers. 2021; 13: 3048.

[32] Sorokine A, Czuzoj-Shulman N, Abenhaim HA. Maternal and neonatal outcomes in women with a history of chemotherapy exposure: a population-based study of 8 million obstetric admissions. Archives of Gynecology and Obstetrics. 2023; 307: 747–753.

[33] Mitchell KB, Johnson HM. Challenges in the management of breast conditions during lactation. Obstetrics and Gynecology Clinics of North America. 2022; 49: 35–55.

[34] Damoiseaux D, Centanni D, Beijnen JH, Amant F, Huitema ADR, Dorlo TPC. Predicting chemotherapy distribution into breast milk for breastfeeding women using a population pharmacokinetic approach. Clinical Pharmacokinetics. 2023; 62: 969–980.

[35] Castanon A, Landy R, Pesola F, Windridge P, Sasieni P. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. The Lancet Public Health. 2018; 3: e34–e43.

[36] Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens. 2023; 12: 298.

[37] McGee AE, Alibegashvili T, Elfgren K, Frey B, Grigore M, Heinonen A, et al. European consensus statement on expert colposcopy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023; 290: 27–37.

[38] Singh N, Rous B, Ganesan R. 2018 FIGO staging system for cervical cancer: summary and comparison with 2009 FIGO staging system. International Journal of Gynecology & Obstetrics. 2019; 145: 129–135.

[39] Alouini S, Rida K, Mathevet P. Cervical cancer complicating pregnancy: implications of laparoscopic lymphadenectomy. Gynecologic Oncology. 2008; 108: 472–477.

[40] Smith HO, Qualls CR, Romero AA, Webb JC, Dorin MH, Padilla LA, et al. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecologic Oncology. 2002; 85: 229–241.

[41] Reed N, Balega J, Barwick T, Buckley L, Burton K, Eminowicz G, et al. British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021; 256: 433–465.

[42] Lyu J, Sun T, Tan X. Ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study. International Journal of Gynecologic Cancer. 2014; 24: 1513–1520.

[43] Tirlapur A, Willmott F, Lloyd P, Brockbank E, Jeyarajah A, Rao K. The management of pregnancy after trachelectomy for early cervical cancer. The Obstetrician & Gynaecologist. 2017; 19: 299–305.

[44] Howe T, Lankester K, Kelly T, Watkins R, Kaushik S. Cervical cancer in pregnancy: diagnosis, staging and treatment. The Obstetrician & Gynaecologist. 2022; 24: 31–39.

[45] Franciszek Dłuski D, Mierzyński R, Poniedziałek-Czajkowska E, Leszczyńska-Gorzelak B. Ovarian cancer and pregnancy—a current problem in perinatal medicine: a comprehensive review. Cancers. 2020; 12: 3795.

[46] Gezginç K, Karataylı R, Yazıcı F, Acar A, Celik C, Capar M. Ovarian cancer during pregnancy. International Journal of Gynecology & Obstetrics. 2011; 115: 140–143.

[47] Oehler MK, Wain GV, Brand A. Gynaecological malignancies in pregnancy: a review. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2003; 43: 414–420.

[48] Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine. 2012; 10: 86.

[49] Bhagat N, Gajjar K. Management of ovarian cysts during pregnancy. Obstetrics, Gynaecology & Reproductive Medicine. 2022; 32: 205–210.

[50] Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. The BMJ. 2010; 341: c6839.

[51] Fauvet R, Brzakowski M, Morice P, Resch B, Marret H, Graesslin O, et al. Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study. Annals of Oncology. 2012; 23: 1481–1487.

[52] Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017; 213: 123–139.

[53] Davenport CF, Rai N, Sharma P, Deeks J, Berhane S, Mallett S, et al. Diagnostic models combining clinical information, ultrasound and biochemical markers for ovarian cancer: Cochrane systematic review and meta-analysis. Cancers. 2022; 14: 3621.

[54] Ngu S, Ngan HYS. Chemotherapy in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2016; 33: 86–101.

[55] Smrz SA, Calo C, Fisher JL, Salani R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. American Journal of Obstetrics and Gynecology. 2021; 224: 506.e1–506.e8.

[56] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[57] Ayhan A, Gunalp S, Karaer C, Gokoz A, Oz U. Endometrial adenocarcinoma in pregnancy. Gynecologic Oncology. 1999; 75: 298–299.

[58] Herrera Cappelletti E, Humann J, Torrejón R, Gambadauro P. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis. Human Reproduction Update. 2022; 28: 282–295.

[59] Yael HK, Lorenza P, Evelina S, Roberto P, Roberto A, Fabrizio S. Incidental endometrial adenocarcinoma in early pregnancy: a case report and review of the literature. International Journal of Gynecologic Cancer. 2009; 19: 1580–1584.

[60] Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology. 2012; 207: 266.e1–266.e12.

[61] Morrison J, Balega J, Buckley L, Clamp A, Crosbie E, Drew Y, et al. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2022; 270: 50–89.

[62] Morrison J, Baldwin P, Buckley L, Cogswell L, Edey K, Faruqi A, et al. British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 252: 502–525.

[63] Cho A, Lee S, Park J, Kim D, Suh D, Kim J, et al. Continued medical treatment for persistent early endometrial cancer in young women. Gynecologic Oncology. 2021; 160: 413–417.

[64] Morrison J, Baldwin P, Buckley L, Cogswell L, Edey K, Faruqi A, et al. British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 252: 502–525.

[65] Pereira Arias-Bouda LM, Vidal-Sicart S, Valdés Olmos RA. Preoperative and intraoperative lymphatic mapping for radioguided sentinel lymph node biopsy in breast cancer. Atlas of Lymphoscintigraphy and Sentinel Node Mapping. 2020; 63: 185–217.

[66] van Maaren MC, Bretveld RW, Jobsen JJ, Veenstra RK, Groothuis-Oudshoorn CG, Struikmans H, et al. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. British Journal of Cancer. 2017; 117: 179–188.

[67] Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. The Lancet Oncology. 2005; 6: 328–333.

[68] DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Clinical gynecologic oncology. 9th edn. Elsevier Health Sciences: Philadelphia. 2017.